There is a slew of recent news about Astellas Pharma Inc., the established Japanese pharmaceutical company. Amidst various reported activities, Astellas has unveiled a new Life Sciences Center in Cambridge, Massachusetts to accelerate breakthrough therapies discovery. Management restructure indicates a push toward a more innovative approach.
Notably, Astellas' VYLOY got approved by the U.S. FDA for treating advanced gastric and GEJ cancer. This oncological achievement is inclusive of Astellas' dedication to tackling hard-to-treat diseases, including Geographic Atrophy. Astellas' izervay for this ailment has gained FDA approval for expanded label, confirming a Class 1 resubmission of the supplemental New Drug Application.
However, it's not all smooth sailing; a recent indictment by China's prosecutors against an Astellas employee and a drug recall due to empty capsules marked some challenging times.
A significant $2.2bn gene therapy deal with AviadoBio Ltd shows Astellas’ strong presence in the gene therapy space. Astellas also announced a collaboration with YASKAWA for innovative cell therapy manufacturing and a license agreement with Sangamo Therapeutics for neurological diseases.
The company is evidently taking strides in innovation and patient engagement. Yet, it appears to echo levels of debt amid broader industry struggles.
Astellas Pharma Inc. News Analytics from Thu, 30 Jun 2022 07:00:00 GMT to Fri, 11 Apr 2025 01:06:13 GMT - Rating 7 - Innovation -2 - Information 8 - Rumor -4
